A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age



Status:Completed
Conditions:Influenza
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:5 - 17
Updated:5/25/2018
Start Date:September 2015
End Date:June 2016

Use our guide to learn which trials are right for you!

A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-Licensed 2015-2016 Quadrivalent Inactivated Comparator Influenza Vaccine (Comparator QIV) in a Pediatric Population 5 Through 17 Years of Age

This is a study to assess the immune (antibody) response and safety of a Seqirus split
virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US
licensed 2015/2016 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric
population 5 through 17 years of age.


Inclusion Criteria:

- Males or females 5 through 17 years of age on the day of first study vaccination.

- Parent or legally acceptable representative able to provide written informed consent
and be willing and able to adhere to all protocol requirements including blood draws.
Participant assent will also be obtained if required.

- If applicable, females of childbearing potential (ie, ovulating, not surgically
sterile) must be abstinent or be willing to use a medically accepted contraceptive
regimen until at least 28 days after the last Study Vaccine. Females of childbearing
potential must return a negative urine pregnancy test result, prior to any vaccination
dose with the Study Vaccine.

Exclusion Criteria:

- History of allergic reactions to egg proteins or any components of the Study Vaccines.

- History of serious adverse reactions to any influenza vaccines.

- History of Guillain-Barré syndrome or other demyelinating disease.

- History of licensed or investigational influenza vaccination in the last 6 months.

- Clinical signs of active infection and/or an oral temperature of ≥ 100°F (37.8°C) on
the day of planned Study Vaccine administration or within 48 hours preceding
vaccination.

- Current or recent, acute or chronic medical conditions that in the opinion of the
Investigator are clinically significant and/or unstable (such as illness
exacerbations) within the preceding 30 days.

- History of any seizures, with the exception of a single febrile seizure.

- Self-reported or known seropositivity suggestive of acute or chronic viral infection
for human immunodeficiency virus, hepatitis B or hepatitis C.

- Known or suspected congenital or acquired immunosuppressive conditions.

- Current or recent immunosuppressive or immunomodulatory therapy, as follows:

- Chronic or long-term systemic corticosteroids: ≥ 0.125 mg/kg/day of oral
prednisolone or equivalent daily;

- Sporadic systemic corticosteroids: ≥ 0.5 mg/kg/day of oral prednisolone or
equivalent for two or more short courses of > 3 days in the 3 months preceding
vaccination;

- Antineoplastic chemotherapy or radiation therapy within the 6 months preceding
vaccination.

Note: Use of topical, inhalant or localised tissue injections of corticosteroids prior to
administration of the Study Vaccine or throughout the study are acceptable.

- Administration of immunoglobulin and/or any blood products within the 3 months
preceding vaccination, or planned administration during the study.

- Participation in a clinical trial or use of an investigational compound within 28 days
prior to the first dose of Study Vaccine, or within 28 days after receiving the final
indicated dose of Study Vaccine, or plans to enter a study during this period.

- Vaccination with a licensed vaccine 28 days (for live or inactivated vaccines) prior
to receiving the first dose of Study Vaccine, or plans to receive any licensed vaccine
prior to the Study Exit Visit.

- Pregnant or lactating females.
We found this trial at
32
sites
?
mi
from
Bellevue, NE
Click here to add this to my saved trials
?
mi
from
Augusta, KS
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
?
mi
from
Binghamton, NY
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
?
mi
from
Cary, NC
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Dayton, OH
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
?
mi
from
Gresham, OR
Click here to add this to my saved trials
?
mi
from
Grove City, OH
Click here to add this to my saved trials
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
?
mi
from
Layton, UT
Click here to add this to my saved trials
?
mi
from
Madera, CA
Click here to add this to my saved trials
?
mi
from
Melbourne, FL
Click here to add this to my saved trials
?
mi
from
Metairie, LA
Click here to add this to my saved trials
?
mi
from
Newton, KS
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Ontario, CA
Click here to add this to my saved trials
?
mi
from
Park City, KS
Click here to add this to my saved trials
?
mi
from
Peoria, IL
Click here to add this to my saved trials
?
mi
from
Redding, CA
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Angelo, TX
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
San Jose, CA
Click here to add this to my saved trials
?
mi
from
Wichita, KS
Click here to add this to my saved trials